

A practical guide for providers on helping patients locate Biktarvy. Five actionable steps, alternative regimens, and workflow tips for HIV clinicians.
As a provider managing HIV patients, you've likely heard from patients who can't find Biktarvy at their pharmacy. It's one of the most frustrating challenges in HIV care right now — not because the drug isn't being made, but because retail pharmacy distribution doesn't always align with specialty medication demand.
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is the most prescribed HIV treatment in the U.S., with 430,000+ active patients. When individual pharmacies run out, the clinical consequences can be real: missed doses, viral rebound risk, and patient anxiety about treatment continuity.
This guide provides five concrete steps you can take to help your patients find and maintain access to Biktarvy, plus workflow tips for your practice.
Biktarvy is not in national shortage as of early 2026. It is not on the FDA Drug Shortage list, and Gilead Sciences reports normal manufacturing capacity. The availability issues are localized pharmacy stock-outs — a distribution problem, not a supply problem.
The challenge is most acute at:
Specialty pharmacies, independent pharmacies with HIV-focused practices, and mail-order pharmacies generally maintain more reliable stock.
Understanding the root causes helps you counsel patients and build better pharmacy relationships:
Before sending a prescription to a specific pharmacy, check whether they actually have Biktarvy in stock. Medfinder for Providers allows you to check real-time inventory across pharmacies in your patient's area.
This simple step — taking 30 seconds at the point of prescribing — can prevent the most common scenario: patient arrives at pharmacy, pharmacy doesn't have it, patient has to start over.
Identify 3-5 pharmacies in your area that reliably stock Biktarvy and other antiretrovirals. Include:
Share this list with your front desk and nursing staff so anyone handling prescription routing can default to reliable pharmacies. Update the list quarterly based on patient feedback.
Many stock-out crises happen because patients wait until the last pill to refill. Build proactive refill reminders into your workflow:
Gilead's Advancing Access program offers multiple layers of support:
Contact: 1-800-226-2056 or gileadadvancingaccess.com. Designate a staff member to manage enrollment for new patients.
If a patient truly cannot access Biktarvy for an extended period, having a pre-considered switch plan prevents reactive decision-making under pressure:
Review each patient's resistance history and co-morbidities proactively so you're not scrambling when availability becomes an issue. See our alternatives to Biktarvy article for patient-facing information you can share.
Integrating medication availability awareness into your practice doesn't require a major overhaul. Here are practical workflow adjustments:
Biktarvy availability challenges are solvable with the right systems in place. The medication isn't in shortage — it's a distribution problem that responds to proactive pharmacy management, reliable stock-checking tools, and strong manufacturer support programs.
Your patients are counting on uninterrupted HIV therapy. A few workflow adjustments can make the difference between a missed dose and seamless care.
Use Medfinder for Providers to check real-time stock, build your preferred pharmacy network, and ensure your patients always know where to fill their Biktarvy prescription.
Related: Biktarvy shortage: what providers need to know in 2026 | How to help patients save money on Biktarvy
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.